Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 31;13(21):5477.
doi: 10.3390/cancers13215477.

Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review

Ana Julia Aguiar de Freitas  1 , Rhafaela Lima Causin  1 , Muriele Bertagna Varuzza  1 , Cassio Murilo Trovo Hidalgo Filho  2 , Vinicius Duval da Silva  3 , Cristiano de Pádua Souza  3 , Márcia Maria Chiquitelli Marques  1   4
Affiliations
Review

Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review

Ana Julia Aguiar de Freitas et al. Cancers (Basel). .

Abstract

Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new "OMICS" technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.

Keywords: breast cancer; molecular biomarkers; neoadjuvant chemotherapy; pathological complete response.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Tumor and liquid biopsies can help identify pCR biomarkers as they can provide information at the genomic (DNA methylation and DNA mutation), transcriptomic (mRNA and miRNA expression), and proteomic (immunohistochemistry) levels.
Figure 2
Figure 2
Summary of the main pCR markers at genomic, transcriptomic, and proteomic levels.
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Harbeck N., Penault-Llorca F., Cortes J., Gnant M., Houssami N., Poortmans P., Ruddy K., Tsang J., Cardoso F. Breast Cancer. Nat. Rev. Dis. Primers. 2019;5:66. doi: 10.1038/s41572-019-0111-2. - DOI - PubMed
    1. Li C.I., Uribe D.J., Daling J.R. Clinical Characteristics of Different Histologic Types of Breast Cancer. Br. J. Cancer. 2005;93:1046–1052. doi: 10.1038/sj.bjc.6602787. - DOI - PMC - PubMed
    1. Prat A., Perou C.M. Deconstructing the Molecular Portraits of Breast Cancer. Mol. Oncol. 2011;5:5–23. doi: 10.1016/j.molonc.2010.11.003. - DOI - PMC - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Long-Term Outcomes for Neoadjuvant versus Adjuvant Chemotherapy in Early Breast Cancer: Meta-Analysis of Individual Patient Data from Ten Randomised Trials. Lancet Oncol. 2018;19:27–39. doi: 10.1016/S1470-2045(17)30777-5. - DOI - PMC - PubMed

LinkOut - more resources